<?xml version="1.0" encoding="UTF-8"?><Articles><Article><id>158</id><JournalTitle>THE PHARMACOLOGY OF ANTIPSYCHOTIC AGENTS: RECEPTOR AFFINITY AND CLINICAL EFFECTS</JournalTitle><Abstract>Schizophrenia is a debilitating and complicated psychiatric disorder which is mainly typified by positive, negative,
and cognitive symptoms. The treatment of antipsychotic drugs has been repeatedly developed, as the use of typical
first-generation antipsychotics were replaced by the second and third-generation drugs, which have extended
therapeutic advantages and minimal amount of side effects. Knowledge of schizophrenia neurobiology to include
the dopamine, serotonin, glutamate, and other neurotransmitter systems has led to the creation of more specific
treatment approaches. The pharmacology of antipsychotic agents is based on their action with the numerous
receptors, especially the dopamine D2 and serotonin 5-HT2A that mediate their clinical manifestation. Recent
treatment options, such as the adoption of multi-target atypical agents, D3-selective targets, and allosteric
modulators are aimed at enhancing the efficacy of treatment and reducing side effects. Personalized medicine, which
is founded on the principles of pharmacogenomics and biomarker-based therapy, has a potential in maximizing the
treatment of schizophrenia patients, treating them and preventing the side effects more accurately</Abstract><Email>anjaliankam554@gmail.com</Email><articletype>Research</articletype><volume>16</volume><issue>1</issue><year>2026</year><keyword>Schizophrenia, Antipsychotics, Receptor Pharmacology, Personalized Medicine, Neurobiology</keyword><AUTHORS>njali A1*, Harsha Vardhini B1, Honey Sriya N1, Navya Sri N1,Dr Purushothaman M</AUTHORS><afflication>Pharm. D, V Year Student, Department of Pharmacy Practice, KLR Pharmacy College, Paloncha, Telangana, India,Professor, Department of Pharmaceutics, KLR Pharmacy College, Paloncha, Telangana, India</afflication></Article></Articles>